Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $119.39
  • 50 Day Moving Average: $119.68
  • 200 Day Moving Average: $116.56
  • 52-Week Range: $2,735,876,000.00 - $91.76
  • Trailing P/E Ratio: 22.25
  • Foreward P/E Ratio: 16.84
  • P/E Growth: 2.73
  • Market Cap: $326.64B
  • Outstanding Shares: 2,735,876,000
  • Beta: 0.61
  • Net Margins: 20.97%
  • Return on Equity: 24.70%
  • Return on Assets: 13.10%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 3.08%
  • Quick Ratio: 2.68%
Additional Links:
Companies Related to Johnson & Johnson:

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $119.40 (0.01% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetDetails
9/19/2016Credit Suisse Group AGReiterated RatingNeutral$123.00View Rating Details
9/13/2016Jefferies GroupLower Price TargetHold$119.00 -> $115.00View Rating Details
9/11/2016Leerink SwannReiterated RatingBuyView Rating Details
9/7/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00View Rating Details
7/20/2016RBC Capital MarketsReiterated RatingOutperform$125.00 -> $133.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00View Rating Details
7/20/2016Royal Bank Of CanadaBoost Price TargetOutperform$125.00 -> $133.00View Rating Details
7/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
7/10/2016Barclays PLCReiterated RatingOverweight$120.00 -> $125.00View Rating Details
6/13/2016Goldman Sachs Group Inc.Set Price TargetNeutral$121.00View Rating Details
5/20/2016Raymond James Financial Inc.Reiterated RatingOutperform$120.00View Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00View Rating Details
5/19/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/20/2016Piper Jaffray Cos.Boost Price TargetNeutral$105.00 -> $106.00View Rating Details
4/20/2016ArgusBoost Price TargetBuy$116.00 -> $130.00View Rating Details
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
4/6/2016Societe GeneraleInitiated CoverageHold$113.00View Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00View Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00View Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00View Rating Details
10/2/2014GuggenheimInitiated CoverageNeutral$115.00View Rating Details
10/1/2014Sanford C. BernsteinDowngradeOutperform -> Market PerformView Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.40 billionViewListenView Earnings Details
1/20/2015Q414$1.26$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.43$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
Current Year EPS Consensus Estimate: $6.68 EPS
Next Year EPS Consensus Estimate: $7.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.60$1.67$1.64
Q2 20163$1.64$1.68$1.66
Q3 20161$1.63$1.63$1.63
Q4 20161$1.59$1.59$1.59
Q1 20172$1.69$1.73$1.71
Q2 20171$1.82$1.82$1.82
Q3 20171$1.82$1.82$1.82
Q4 20171$1.79$1.79$1.79
Q1 20181$1.91$1.91$1.91
Q2 20181$2.00$2.00$2.00
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Annual Dividend:$3.20
Dividend Yield:2.68%
Dividend Growth:7.10% (3 Year Average)
Payout Ratio:60.15% (Based on Trailing 12 Months of Earnings)
47.90% (Based on Current Year Consensus EPS Estimate)
45.13% (Based on Next Year Consensus EPS Estimate)
Track Record:53 Years of Consecutive Dividend Growth

Dividend History for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Johnson & Johnson (NYSE:JNJ)
News IconJ&J invests in, licenses oncology candidates to microcap Tracon (NYSE:JNJ) - September 28 at 5:35 PM logoAriel Funds Comments on Johnson & Johnson (NYSE:JNJ) - September 28 at 5:35 PM logoJohnson & Johnson: Buying The Dips Beats The Drips - Timing Not An Issue (NYSE:JNJ) - September 28 at 5:35 PM logoRatings on the Largest Stocks - Buy, Neutral or Avoid (NYSE:JNJ) - September 28 at 5:35 PM logoBetter Buy: Johnson & Johnson vs. AbbVie (NYSE:JNJ) - September 28 at 4:21 PM logoWhy Johnson & Johnson's New Wearable for Diabetics Should Be a Home Run (NYSE:JNJ) - September 28 at 11:43 AM
News IconNotable Traders Watch List: Johnson & Johnson (NYSE:JNJ), LinkedIn Corp (NYSE:LNKD) - NYSE Journal (press release) (NYSE:JNJ) - September 28 at 10:39 AM logoJohnson & Johnson (JNJ): Notes From Management Meetings - UBS - (NYSE:JNJ) - September 28 at 10:39 AM logoBlockbuster biotech deal coming? (NYSE:JNJ) - September 28 at 10:39 AM logoJohnson & Johnson On Track Ror Rally (NYSE:JNJ) - September 27 at 10:22 AM logoInteresting January 2017 Stock Options for JNJ (NYSE:JNJ) - September 27 at 10:22 AM logoJohnson & Johnson Becomes #14 Most Shorted Dow Stock, Replacing Intel (NYSE:JNJ) - September 27 at 10:22 AM logoThe 3 Best-Run Companies in the Healthcare Sector (NYSE:JNJ) - September 27 at 10:22 AM logoInteresting January 2017 Stock Options for JNJ - Nasdaq (NYSE:JNJ) - September 26 at 5:50 PM
News IconAnalysts Valuations For Two Stocks: Johnson & Johnson (NYSE:JNJ ... - The Voice Registrar (NYSE:JNJ) - September 26 at 5:50 PM logoNew Crohn's Disease Drug Approved by FDA - 24/7 Wall St. (NYSE:JNJ) - September 26 at 5:50 PM
News IconIt's Earnings Time: What to Do with Johnson & Johnson (NYSE:JNJ) Stock - The Voice Registrar (NYSE:JNJ) - September 26 at 5:50 PM logoFDA OKs Johnson & Johnson's Stelara for Crohn's disease (NYSE:JNJ) - September 26 at 10:30 AM
News IconStock under Review - Johnson & Johnson (NYSE:JNJ) - Hot Stocks Point (NYSE:JNJ) - September 26 at 10:24 AM logoResearch finds talc doesn't cause cancer; juries disagree (NYSE:JNJ) - September 26 at 10:24 AM logoMcDonald's (MCD), Johnson & Johnson (JNJ) Among Hedge Funds' Favorite Dividend Aristocrats - Insider Monkey (blog) (NYSE:JNJ) - September 24 at 5:20 PM
News IconMcDonald’s (MCD), Johnson & Johnson (JNJ) Among Hedge Funds’ Favorite Dividend Aristocrats (NYSE:JNJ) - September 24 at 12:21 PM logoBetter Buy: Pfizer Inc. vs. Johnson & Johnson - Motley Fool (NYSE:JNJ) - September 24 at 10:13 AM logo8:03 am Johnson & Johnson subsidiary Janssen submits a BLA to the FDA seeking approval of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis (NYSE:JNJ) - September 24 at 10:13 AM logoProcter & Gamble Is Losing Shelf Space Clout (NYSE:JNJ) - September 23 at 5:25 PM logoA Look at Johnson & Johnson’s Recent Stock Performance (NYSE:JNJ) - September 23 at 5:25 PM logoHate Risk? You'll Love These 3 Stocks (NYSE:JNJ) - September 23 at 5:25 PM logoThe Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics (NYSE:JNJ) - September 23 at 5:25 PM logoBetter Buy: Pfizer Inc. vs. Johnson & Johnson (NYSE:JNJ) - September 23 at 8:54 AM logoHow Much Could DepoMed Fetch in a Deal? (NYSE:JNJ) - September 22 at 3:56 PM
News IconJohnson & Johnson Advances Commitment to Improve Global Health and Well-Being (NYSE:JNJ) - September 22 at 8:57 AM logoJohnson & Johnson: From Dead Money To Amongst The Best In My Portfolio (NYSE:JNJ) - September 22 at 8:57 AM logoBetter Buy: Procter & Gamble vs. Johnson & Johnson (NYSE:JNJ) - September 21 at 7:19 PM
News IconActive Stock's Momentum: SolarCity Corp (NASDAQ:SCTY), Johnson & Johnson (NYSE:JNJ) - NYSE Journal (press release) (NYSE:JNJ) - September 21 at 4:00 PM
News IconFord Motor Company (NYSE:F) & Johnson & Johnson (NYSE:JNJ) Watch List - Money News (NYSE:JNJ) - September 21 at 4:00 PM logoJohnson & Johnson (JNJ)'s Janssen Builds On Partnership With Geron Corporation (GERN) - Insider Monkey (blog) (NYSE:JNJ) - September 21 at 4:00 PM
News IconJohnson & Johnson (JNJ)’s Janssen Builds On Partnership With Geron Corporation (GERN) (NYSE:JNJ) - September 21 at 1:10 PM logoJohnson & Johnson (NYSE:JNJ) Janssen Builds On Partnership With Geron Corporation (NASDAQ:GERN) - Market Exclusive (NYSE:JNJ) - September 21 at 9:55 AM logoWho's Got The Best Pipeline: Pfizer, Merck Or Johnson & Johnson? - Seeking Alpha (NYSE:JNJ) - September 21 at 9:55 AM
News IconAnalysts Valuations For Two Stocks: Johnson & Johnson (NYSE:JNJ), Marriott International Inc (NASDAQ:MAR) - The Voice Registrar (NYSE:JNJ) - September 21 at 9:55 AM logoJohnson & Johnson's Smart (Yet Surprising) Acquisition - Motley Fool (NYSE:JNJ) - September 21 at 9:55 AM logoJohnson & Johnson Acquires Abbott's Medical Optics Unit And Investor Takeaways (NYSE:JNJ) - September 20 at 10:52 AM logoA Breakdown Here In This Sector Would Not Be Healthy (NYSE:JNJ) - September 20 at 10:52 AM logoJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results (NYSE:JNJ) - September 20 at 10:52 AM featured highlights: Baxter International, AO Smith, Johnson & Johnson, BWX Technologies and Lancaster Colony (NYSE:JNJ) - September 20 at 10:52 AM logoJOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSE:JNJ) - September 19 at 5:46 PM logoAbbott Laboratories -- Moody's expectations for Abbott's ratings unchanged following news of medical optics sale (NYSE:JNJ) - September 19 at 5:46 PM logoJohnson & Johnson : Blog Coverage Johnson & Johnson Acquires Abbott Laboratories Optic Unit (NYSE:JNJ) - September 19 at 10:18 AM logoThis Is The Biggest Reason To Buy Johnson & Johnson (Hint, It Has Nothing To Do With The Dividend) (NYSE:JNJ) - September 19 at 10:18 AM logoJ&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion (NYSE:JNJ) - September 19 at 10:18 AM


Johnson & Johnson (NYSE:JNJ) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff